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Epithelial-myoepithelialcarcinoma(EMC)ofthelungisrareandisconsideredtobelow-grademalignancy.Intracranialmetastasis
of pulmonary EMC has not previously been reported according to our search of the literature. We report a case of skull metastasis
as the initial manifestation of pulmonary EMC. An 81-year-old man complained of left leg motor weakness. Neurological
examination showed left hemiparesis. Computed tomography and magnetic resonance imaging revealed an osteolytic tumor in
the right frontal bone with invasion to the dura and subdural space, attached to the superior sagittal sinus. Subtotal removal of
the tumor was performed, and the left hemiparesis showed improvement. Histopathological study revealed the tumor to consist
of epithelial and myoepithelial cells. Pulmonary EMC was diagnosed. The MIB-1 index in primary lesion was approximately 10%.
The skull and dura are possible sites for metastasis from pulmonary EMC. The MIB-1 index is a predictive marker of malignant
potential.
1.Introduction
Epithelial-myoepithelial carcinoma (EMC) of the lung is
rare and is considered to be low-grade malignancy. To date,
approximately 20 cases have been reported in the English
literature [1]. Intracranial metastasis of pulmonary EMC has
not previously been reported according to our search of the
literature. We report a case of skull metastasis as the initial
manifestation of pulmonary EMC and discuss its malignant
potential.
2. Case Presentation
An 81-year-old man was admitted to our hospital with
a chief complaint of left leg motor weakness for one
week. Neurological examination showed left hemiparesis
(manual muscle test 4/5). Physical examination showed a
subcutaneous tumor measuring 40 × 30mm in the right
frontal region. The tumor was not mobile and painless.
Normal skin covered the tumor. There was no skin rash over
the tumor. The patient had a medical history of prostate
cancer at the age of 78 years. The prostate cancer had been
totally resected with no signs of recurrence for 3 years.
The patient had no smoking history. Laboratory studies
showed the serum prostate-speciﬁc antigen level to be 1.763
(0–4)ng/mL. Skull radiography and computed tomography
(CT) showed an osteolytic tumor in the right frontal bone
(Figure 1(a)). Magnetic resonance imaging (MRI) showed
a heterointense tumor with perifocal edema on both T1-
and T2-weighted images, which was enhanced heteroge-
neously by gadolinium-diethylenetriaminepenta-acetic acid
(Gd-DTPA). The tumor was attached to the wall of the
superior sagittal sinus and dura of the right frontal lobe
(Figures 1(b) and 1(c)). The preoperative workup included2 Case Reports in Oncological Medicine
(a) (b)
(c) (d)
Figure 1: Computed tomographic scan of the brain shows an osteolytic tumor in the right frontal region (a). Coronal (b) and sagittal (c)
T1-weighted magnetic resonance images with gadolinium-diethylenetriaminepenta-acetic acid revealing a heterogeneously enhanced tumor
in the right frontal region with perifocal edema. The tumor was attached to the wall of the superior sagittal sinus and dura. Computed
tomographic scan of the chest reveals an endobronchial growth in the hilum of the right upper lobe (d).
(a)
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Figure 2: Intraoperative photographs of the tumor. (a) Complete exposure of the tumor covered by the periosteum. (b) Resected tumor
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Figure 3: (a) Tubular structures with an inner layer of cuboidal epithelial cells and an outer layer of myoepithelial cells with clear cytoplasm.
Mitoses were not conspicuous (hematoxylin-eosin, original magniﬁcation ×200). (b) Immunoreactivity in epithelial cells for cytokeratin
(original magniﬁcation ×200). (c) Immunoreactivity in myoepithelial cells for p63 (original magniﬁcation ×200). (d) Immunoreactivity for
the MIB-1 was about 10% (original magniﬁcation ×200).
CT of the chest, abdomen, and pelvis, which demonstrated
a right lung tumor with subcarinal lymph node swelling
and pulmonary emphysema (Figure 1(d)). No other tumors,
such as in the salivary gland and breast, were found. A wide
scalp incision and craniotomy were performed with a 2-cm
rim of bone over the superior sagittal sinus and tumor. The
tumorwasexcisedthroughtheperiosteumcoveringthebone
(Figure 2(a)), and the margins were negative (Figure 2(b)).
The tumor was attached to the wall of the superior sagittal
sinus and surface of the brain. Subtotal resection was
performed under a microscope. Dural plasty was conducted
using a GORE-TEX surgical membrane. A titanium mesh
plate was placed over the skull defect. Histologically, the
tumor showed biphasic architecture, composed of glands
and spindle cells. The glands had a double layer of cells.
The inner cells were ﬂattened or cuboidal with pink cyto-
plasm. The outer cells were round or polygonal and exhib-
ited either clear or eosinophilic cytoplasm (Figure 3(a)).
The inner cells showed immunoreactivity for cytokeratins
(Figure 3(b)). The outer cells showed immunoreactivity for
p63 (Figure 3(c)) and S-100, but not for TTF-1. The MIB-1
labeling index was approximately 10% in myoepithelial cells
(Figure 3(d)). No necrosis was observed. Mitoses were not
conspicuous. We diagnosed the tumor as EMC. Postopera-
tively,thepatient’slefthemiparesisimprovedcompletely,and
no neurological deterioration manifested. A bronchoscopic
biopsy was performed. The lung tumor was conﬁrmed to be
an EMC. Further examinations of the parotid and salivary
glands were performed by an otolaryngologist, but no other
tumors were detected. We concluded that pulmonary EMC
had metastasized to the dura and skull. The MIB-1 index
in primary lesion was approximately 10%. Whole brain
radiation therapy (30Gy) was then administered. For the
lung tumor, best supportive care was provided for the will
of the patient.
3. Discussion
The tracheobronchial submucosal glands are the pulmonary
counterpart of the salivary gland system. EMCs originating
from bronchial submucosal glands are very rare. To date,
approximately 20 cases have been reported in the English
literature [1]. Doganay et al. reported a case with a review
of 7 other cases in 2003. The patients were in the ﬁfth to
seventh decades of life, and 50% were male [2]. The clinical
course of EMC is unknown. EMC is considered to be a
low-grade tumor [3, 4], and treatment by complete surgical
resection with negative margins is recommended [5, 6].
Some authors have pointed out its malignant potential, but
little is known about the biological potential of EMC due to4 Case Reports in Oncological Medicine
limited follow-up data [6–10]. However, even in a case with
recurrence, local resection kept the patient asymptomatic
for 4 years [1]. Intracranial metastasis of pulmonary EMC
has not previously been reported, according to our search
of the literature. Our case presentation seems to be the ﬁrst
of pulmonary EMC found after metastasis to the skull and
dura hematogenously. Therefore, we felt it is important to
report this case. Histologically, all lesions share the common
features of having duct-like structures within a background
of variable proportions of epithelial and myoepithelial cells
[6]. The inner layer consists of small darker cuboidal
epithelial cells (positive for cytokeratin, negative for S-100
and muscle-speciﬁc actin), while the outer layer is formed by
clear myoepithelial cells (positive for S-100, muscle-speciﬁc
actin, and P63 with focal weak positivity for cytokeratin) [3,
4, 6, 11]. As to the malignant potential of pulmonary EMC,
samples obtained from the primary and metastatic regions
in our case did not show prognostic factors such as mitoses
or necrosis. Only immunoreactivity for the MIB-1 index
in primary and metastatic lesions, up to 10%, suggested
malignant potential.
4. Conclusions
The skull and dura are possible sites of metastasis from
pulmonary EMC. The MIB-1 index is a marker predicting
malignant potential.
Conﬂict of Interests
The authors declare that there is no conﬂict of interests.
Consent
The patient’s consent has been obtained.
References
[1] A. A. Muslimani, M. Kundranda, S. Jain, and H. A. Daw,
“Recurrent bronchial epithelial-myoepithelial carcinoma after
local therapy,” Clinical Lung Cancer, vol. 8, no. 6, pp. 386–388,
2007.
[ 2 ]L .D o g a n a y ,S .B i l g i ,A .O z d i l ,Y .Y o r u k ,S .A l t a n e r ,a n dK .
Kutlu, “Epithelial-myoepithelial carcinoma of the lung: a case
report and review of the literature,” Archives of Pathology &
Laboratory Medicine, vol. 127, no. 4, pp. e177–180, 2003.
[3] A.R uska,Z.K erek es,E.H ov ork ov´ a,andP.Bartoˇ n,“Epithelial-
myoepithelial carcinoma of the bronchus,” Pathology Research
and Practice, vol. 194, no. 6, pp. 431–435, 1998.
[4] R. W. Wilson and C. A. Moran, “Epithelial-myoepithelial car-
cinomaofthelung:immunohistochemicalandultrastructural
observations and review of the literature,” Human Pathology,
vol. 28, no. 5, pp. 631–635, 1997.
[ 5 ]D .Y .K a n g ,Y .S .Y o o n ,H .K .K i me ta l . ,“ P r i m a r ys a l i v a r y
gland-type lung cancer: surgical outcomes,” Lung Cancer, vol.
72, pp. 250–254, 2010.
[6] C. V. Nguyen, S. Sister, and C. A. Moran, “Pulmonary
epithelial-myoepithelial carcinoma: a clinicopathologic and
immunohistochemical study of 5 cases,” Human Pathology,
vol. 40, no. 3, pp. 366–373, 2009.
[7] L. G. Fulford, Y. Kamata, K. Okudera et al., “Epithelial-
myoepithelial carcinomas of the bronchus,” American Journal
of Surgical Pathology, vol. 25, no. 12, pp. 1508–1514, 2001.
[8] M. M. Hayes, N. G. van der Westhuizen, and R. Forgie,
“Malignant mixed tumor of bronchus: a biphasic neoplasm of
epithelial and myoepithelial cells,” Modern Pathology, vol. 6,
no. 1, pp. 85–88, 1993.
[9] B. Papla, K. Gal ¸zka, and E. Malinowski, “Epithelial-myoe-
pithelial carcinoma of the bronchus,” Polish Journal of Pathol-
ogy, vol. 51, no. 3, pp. 153–157, 2000.
[10] A. Rosenfeld, D. Schwartz, S. Garzon, and S. Chaleﬀ, “Epithe-
lial-myoepithelial carcinoma of the lung: a case report
and review of the literature,” Journal of Pediatric Hematol-
ogy/Oncology, vol. 31, no. 3, pp. 206–208, 2009.
[11] G. Pelosi, F. Fraggetta, F. Maﬃni, P. Solli, A. Cavallon,
and G. Viale, “Pulmonary epithelial-myoepithelial tumor of
unproven malignant potential: report of a case and review of
the literature,” Modern Pathology, vol. 14, no. 5, pp. 521–526,
2001.